Suven Pharmaceuticals Ltd

Suven Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Suven Pharmaceuticals Ltd

₹ 646 0.72%
25 Apr 4:01 p.m.
suvenpharm.com BSE: 543064 NSE : SUVENPHAR
About

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Key Points

Business Segments
CDMO (Development projects and Commercial supplies)
SPL engages in NCE molecule development and supply of intermediates. This is a high-value-add, high-margin business. SPL supplies intermediates for four molecules addressing rheumatoid arthritis, diabetes, depression and women’s health[1].The company has a strong order book with new clients being consistently added. Most clients are the Big Pharma companies in Europe and the US. The company is looking to shift from Intermediate to API manufacturing and is in discussion with clients regarding this. The company has stated that it has the facilities for API manufacturing.[2]

Website BSE NSE
  • Market Cap ₹ 16,570 Cr.
  • Current Price ₹ 646
  • High / Low ₹ 768 / 427
  • Stock P/E 43.4
  • Book Value ₹ 76.5
  • Dividend Yield 0.15 %
  • ROCE 33.6 %
  • ROE 25.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 33.0%
  • Company has been maintaining a healthy dividend payout of 24.9%
  • Debtor days have improved from 44.2 to 30.1 days.

Cons

  • Stock is trading at 8.44 times its book value
  • Promoter holding has decreased over last quarter: -9.90%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
275 259 264 301 392 364 339 278 348 364 344 225 213
138 165 149 179 206 206 184 172 201 190 174 127 145
Operating Profit 137 94 115 122 186 158 155 107 147 175 170 97 68
OPM % 50% 36% 43% 40% 48% 43% 46% 38% 42% 48% 49% 43% 32%
5 3 6 38 9 134 11 10 13 11 10 14 14
Interest 2 2 2 1 1 2 1 0 1 2 1 0 1
Depreciation 9 8 9 9 11 10 11 11 11 11 11 10 11
Profit before tax 132 87 109 150 184 279 154 106 147 172 168 101 70
Tax % 26% 26% 25% 23% 26% 20% 26% 26% 26% 25% 26% 26% 25%
98 64 81 115 137 224 114 79 109 130 124 75 52
EPS in Rs 3.84 2.53 3.20 4.53 5.38 8.82 4.48 3.10 4.30 5.11 4.88 2.94 2.06
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
378 834 1,010 1,320 1,330 1,146
206 449 567 738 740 636
Operating Profit 172 385 443 582 590 510
OPM % 45% 46% 44% 44% 44% 45%
1 18 14 188 45 49
Interest 3 22 12 9 13 5
Depreciation 12 24 32 39 43 44
Profit before tax 158 358 414 722 579 510
Tax % 31% 24% 25% 23% 25%
109 270 309 558 433 382
EPS in Rs 5,463.50 10.61 12.12 21.92 16.99 14.99
Dividend Payout % 0% 24% 16% 23% 35%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 17%
TTM: -14%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 17%
TTM: -28%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 6%
1 Year: 36%
Return on Equity
10 Years: %
5 Years: %
3 Years: 33%
Last Year: 26%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 13 25 25 25 25
Reserves 578 770 1,040 1,495 1,724 1,923
83 186 143 97 70 51
123 142 151 187 139 110
Total Liabilities 783 1,111 1,359 1,805 1,958 2,109
271 357 441 534 512 502
CWIP 111 102 96 30 165 172
Investments 7 276 426 600 710 953
394 376 395 641 571 482
Total Assets 783 1,111 1,359 1,805 1,958 2,109

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
50 359 329 270 484
-65 -367 -258 -90 -236
26 9 -76 -156 -236
Net Cash Flow 11 1 -4 23 13

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 142 51 37 65 30
Inventory Days 556 278 243 259 284
Days Payable 190 113 100 97 56
Cash Conversion Cycle 509 217 180 228 258
Working Capital Days 285 105 95 126 117
ROCE % 46% 39% 50% 34%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 50.10%
7.93% 8.03% 8.25% 8.56% 8.49% 7.58% 8.11% 9.47% 9.50% 10.01% 10.14% 9.54%
5.45% 5.81% 5.93% 6.56% 6.96% 10.87% 11.36% 11.43% 10.63% 14.13% 15.94% 17.24%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01%
26.62% 26.16% 25.82% 24.88% 24.55% 21.56% 20.55% 19.10% 19.88% 15.85% 13.93% 23.11%
No. of Shareholders 92,66996,53286,44785,72586,08882,57779,41272,88572,16773,71570,05268,932

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls